Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CMT1X phenotypes represent loss of GJB1 gene function.

M E Shy1, C Siskind, E R Swan

  • 1Department of Neurology, Wayne State University, 421 E. Canfield, Detroit, MI 48201, USA. m.shy@wayne.edu

Neurology
|March 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

Journal of the peripheral nervous system : JPNS·2024
Same author

The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy.

Science (New York, N.Y.)·2021
Same author

Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Brain research·2020
Same author

Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype.

Journal of neurology·2019
Same author

Heterozygous Null Mutation in the P<sub>0</sub> Gene Associated with Mild Charcot-Marie-Tooth Disease.

Annals of the New York Academy of Sciences·2017
Same author

Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors.

Clinical radiology·2017

Most Charcot-Marie-Tooth type 1X (CMT1X) patients experience worsening disability with age. This suggests GJB1 mutations cause neuropathy via loss of connexin 32 function, potentially treatable with gene therapy.

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Charcot-Marie-Tooth type 1X (CMT1X) arises from over 260 mutations in the GJB1 gene, encoding connexin 32 (Cx32).
  • The natural progression and mutation-specific severity of CMT1X are not well understood.
  • The role of gain-of-function mechanisms in CMT1X pathogenesis remains unclear.

Purpose of the Study:

  • To explore genotype-phenotype correlations in CMT1X.
  • To characterize the natural history of CMT1X in male patients.

Main Methods:

  • Evaluated 73 male patients with CMT1X, each harboring one of 28 distinct GJB1 mutations.
  • Quantitatively assessed disability using the CMT Neuropathy Score (CMTNS), CMT Symptom Score (CMTSS), and CMT Examination Score (CMTES).
  • Utilized neurophysiological assessments, including motor unit number estimates.

Related Experiment Videos

Main Results:

  • Patient disability progressively increased with age.
  • Disability levels were comparable to those seen with GJB1 deletions.
  • A significant correlation was observed between disability and the loss of motor units.

Conclusions:

  • The findings indicate that most GJB1 mutations lead to neuropathy through a loss of normal connexin 32 function.
  • This loss-of-function mechanism suggests potential therapeutic benefits from gene replacement strategies for male CMT1X patients.